2Q PREVIEW: Gilead's HIV therapies still carry the day
This article was originally published in Scrip
While Gilead Sciences’ stock trades on hope for its hepatitis C drug program, the company’s earnings are still dependent on a dominant hold on the HIV therapy market.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.